NXL
Nexalin Technology, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$5.06
−5.60%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
Market Cap
$4.33M
MomentumView details →
1D Return
−5.60%
YTD Return
+779.93%
RSI (14)
67.8
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
Market Cap
$4.33M
RSI (14)
67.8
MomentumView details →
1D Return
−5.60%
YTD Return
+779.93%
SummaryUpdated Jun 1, 2026
Nexalin Technology, Inc. (NASDAQ:NXL) is a medical device company founded in 2021 and headquartered in Houston, Texas. The company went public in September 2022 and specializes in developing neurostimulation products for treating mental health conditions. Nexalin focuses on non-invasive, drug-free therapeutic devices that use proprietary frequency-based waveforms to stimulate brain structures associated with various mental health disorders.
Similar companies
Latest newsMore news →
Carolyn Shelton departed as Senior Vice President of Quality, Regulatory, and Clinical Affairs at Nexalin Technology, Inc., effective August 28, 2026, with severance including one month of base salary, a $20,000 bonus for 2026, accelerated stock option vesting, and health insurance subsidy through September 30, 2026.2d agoNexalin Technology, Inc. received a notice from Nasdaq on 2026-08-14 for non-compliance with the Stockholders' Equity Requirement (Rule 5550(b)(1)) and requested a hearing before the Nasdaq Hearing Panel to present its remediation plan.19d ago